Know Cancer

forgot password

Phase I/II Trial of Sorafenib and Weekly Bortezomib in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/Phase 2
18 Years
Not Enrolling
Multiple Myeloma

Thank you

Trial Information

Phase I/II Trial of Sorafenib and Weekly Bortezomib in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Primary Objective:

To evaluate the efficacy of sorafenib with weekly bortezomib, as measured by objective
response rate and progression-free survival in patients with relapsed/refractory multiple

Secondary Objective:

To evaluate the feasibility and toxicity of sorafenib with weekly bortezomib in the
treatment of patients with relapsed/refractory multiple myeloma.

Inclusion Criteria:

- Eligible participants must have been previously diagnosed using standard criteria and
have received no more than 2 prior regimens for the treatment of multiple myeloma.

- Participant must be defined as Relapsed or Refractory Disease by one of the following
criteria prior to enrollment: Relapsed Disease after high-dose therapy (autologous
stem cell transplantation) as part of the first-line line treatment program. These
patients may have received a maximum of 1 previous regimen, Refractory Disease or
Relapsed Disease after > 1 prior therapy for multiple myeloma. Prior bortezomib
treatment permitted if the patient achieved a documented response.

- ECOG performance status 0, 1, or 2.

- WBC >= 3000; ANC >= 1000; platelets >= 50,000 (Patients with platelets >= 30,000 are
eligible if thrombocytopenia is felt to be due to extensive bone marrow involvement
with myeloma).

- Serum creatinine < 2.0 mg/dL for a calculated or measured creatinine clearance > 30

- Total bilirubin < 1.5 x ULN

- ALT and AST < 2.5 x the ULN ( < 5 x ULN for patients with liver involvement)

- INR < 1.5 or a PT/PTT within normal limits. Patients receiving anti-coagulation
treatment with an agent such as warfarin or heparin may be allowed to participate.
For patients on warfarin, the INR should be measured prior to initiation of sorafenib
and monitored at least weekly, or as defined by the local standard of care, until INR
is stable.

- Patients must have measurable or evaluable disease. In patients with disease limited
to bone and bone marrow, serial paraprotein measurements are acceptable for evaluable

Exclusion Criteria:

- Patients with > grade 1 peripheral neuropathy.

- Thrombolic or embolic events such as a cerebrovascular accident, including transient
ischemic attacks, within the past 6 months.

- Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of
study drug.

- Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of
study drug.

- Known brain metastasis. Patients with neurological symptoms must undergo CT scan/MRI
of the brain to exclude brain metastasis.

- Patients with other medical conditions that would potentially interfere with their
participation in this trial.

- Patients with other active malignancies, or history of treatment for other invasive
cancers, within 3 years of study entry.

- Patients with previous evidence of hypersensitivity to sorafenib, bortezomib, boron,
or mannitol.

- Women who are pregnant or lactating are ineligible. All patients of childbearing
potential are required to use adequate methods of contraception while receiving study
treatment, and for at least 2 weeks after the last dose of sorafenib. Men should
continue to use contraception until at least 3 months after their last dose of

- Evidence of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal
gammopathy, and skin changes) syndrome.

- Cardiac disease: Congestive heart failure > class II NYHA (see Appendix D.) Patients
must not have unstable angina (anginal symptoms at rest), new onset angina (began
within the last 3 months), or myocardial infarction within the past 6 months.

- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.

- Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic
pressure > 90 mmHg, despite optimal medical management.

- Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.

- Active clinically serious infection > CTCAE Grade 2.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment

Outcome Description:

The percentage of patients who experience an objective benefit from treatment, determined by the treating physician after reviewing key laboratory values from blood and urine.

Outcome Time Frame:

24 months

Safety Issue:


Principal Investigator

Ian W. Flinn, M.D.

Investigator Role:

Study Chair

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Institutional Review Board

Study ID:




Start Date:

November 2007

Completion Date:

August 2010

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Relapsed
  • Refractory
  • Sorafenib
  • Bortezomib
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



Center for Cancer and Blood DisordersBethesda, Maryland  20817
Tennessee Oncology, PLLCClarksville, Tennessee  37043